BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript
Operator Good day and Welcome to the BioCryst third-quarter 2024 earnings call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference over to John Bluth,
BioCryst: Q3 Earnings Snapshot
(BCRX) on Monday reported a loss of $14 million in its third quarter. The Durham, North Carolina-based company said it had a
Creatd: Q3 Earnings Snapshot
Creatd: Q3 Earnings Snapshot
Akoya: Q3 Earnings Snapshot
Akoya Biosciences Inc. (AKYA)
Beam Global: Q3 Earnings Snapshot
On a per-share basis, the San Diego-based company said it had profit of 9 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 16 cents per share.
Pieris Pharmaceuticals: Q3 Earnings Snapshot
Pieris Pharmaceuticals Inc. (PIRS) on Wednesday reported a loss of $2.9 million in its third quarter. On a per-share basis, the Boston-based company said it had a loss of $2.19. This story was generated by Automated Insights ( using data from Zacks Investment Research.
Galmed Pharmaceuticals: Q3 Earnings Snapshot
(GLMD) on Thursday reported a loss of $1.9 million in its third quarter. The Ramat Gan, Israel-based company said it had a loss of $2.31 per share. This story was generated by Automated Insights ( using data from Zacks Investment Research.
ClearOne: Q3 Earnings Snapshot
(CLRO) on Friday reported
VolitionRX: Q3 Earnings Snapshot
None
Business Insider1d
BioCryst (BCRX) Receives a Buy from Bank of America Securities
Begin your TipRanks Premium journey today. BioCryst (BCRX) Company Description: BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes ...
ETF Daily News3d
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $14.67 Average Target Price from Analysts
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have earned a consensus recommendation of ...
Drugmaker eyes billion-dollar pill
A Durham company says its drug is pacing for over $400 million in revenue this year. The goal is $1 billion.
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today reported financial results for the third quarter ended September 30, 2024, and ...
ETF Daily News13d
BioCryst Pharmaceuticals (BCRX) Set to Announce Earnings on Monday
Several analysts have issued reports on BCRX shares. JMP Securities raised their price target on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform ...
Nasdaq11d
BioCryst Pharmaceuticals Reports Strong Q3 2024 Results
BioCryst Pharmaceuticals ( (BCRX)) has released its Q3 earnings. Here is a breakdown of the information BioCryst Pharmaceuticals presented to its investors. BioCryst Pharmaceuticals is a ...